BIO 2015 Dispatches: Antibiotics: Uninteresting to investors, tough to find advocates
This article was originally published in Scrip
Executive Summary
There are a number of factors why industry has been hesitant to invest in new antibiotics, said Dr Julie Gerberding, executive vice president of strategic communications, global public policy and population health at Merck and the former director of the Centers for Disease Control and Prevention (CDC) during the George W Bush administration.